{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:35:47Z","timestamp":1789544147002,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10549-020-05970-2","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T08:02:54Z","timestamp":1602921774000},"page":"657-666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?"],"prefix":"10.1007","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3398-0570","authenticated-orcid":false,"given":"Amparo","family":"Garcia-Tejedor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Fernandez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Gil-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Perez-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eulalia","family":"Fernandez-Montol\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostina","family":"Stradella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Recalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Bajen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Benitez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Guma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Pla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Laplana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Pernas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Perez-Sildekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Catala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Falo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,17]]},"reference":[{"issue":"2","key":"5970_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1200\/JOP.2010.000136","volume":"7","author":"KM Cavanaugh","year":"2011","unstructured":"Cavanaugh KM (2011) Effects of early exercise on the development of lymphedema in patients with breast cancer treated with axillary lymph node dissection. J Oncol Pract 7(2):89\u201393","journal-title":"J Oncol Pract"},{"issue":"10","key":"5970_CR2","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ et al (2016) Improved axillary evaluation following neoadjuvant therapy for patientswith node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 34(10):1072\u20131078","journal-title":"J Clin Oncol"},{"key":"5970_CR3","doi-asserted-by":"crossref","unstructured":"Schwartz GF, Veronesi U, Clough KB, Dixon JM, Fentiman IS, Heywang-K\u00f6brunner SH et al (2006) In: Proceedings of the consensus conference on breast conservation, April 28 to May 1, 2005, Milan, Italy. Cancer 107(2):242\u2013250. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16770785. Accessed 2 Oct 2014","DOI":"10.1002\/cncr.21988"},{"issue":"6","key":"5970_CR4","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa012782","volume":"349","author":"U Veronesi","year":"2003","unstructured":"Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349(6):546\u2013553","journal-title":"N Engl J Med"},{"issue":"10","key":"5970_CR5","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11(10):927\u2013933. https:\/\/doi.org\/10.1016\/S1470-2045(10)70207-2","journal-title":"Lancet Oncol"},{"issue":"12","key":"5970_CR6","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1200\/JCO.2005.05.188","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B et al (2005) Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23(12):2694\u20132702","journal-title":"J Clin Oncol"},{"issue":"12","key":"5970_CR7","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1007\/s00268-012-1704-z","volume":"36","author":"M Takahashi","year":"2012","unstructured":"Takahashi M, Jinno H, Hayashida T, Sakata M, Asakura K, Kitagawa Y (2012) Correlation between clinical nodal status and sentinel lymph node biopsy false negative rate after neoadjuvant chemotherapy. World J Surg 36(12):2847\u20132852","journal-title":"World J Surg"},{"issue":"10","key":"5970_CR8","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1245\/s10434-012-2484-2","volume":"19","author":"R Alvarado","year":"2012","unstructured":"Alvarado R, Yi M, Le-Petross H, Gilcrease M, Mittendorf EA, Bedrosian I et al (2012) The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol 19(10):3177\u20133184","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"5970_CR9","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1200\/JCO.2008.18.3228","volume":"27","author":"JM Classe","year":"2009","unstructured":"Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J et al (2009) Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of ganglion sentinelle et chimioth\u00e9rapie neoadjuvante, a French prospective multicentric study. J Clin Oncol 27(5):726\u2013732","journal-title":"J Clin Oncol"},{"issue":"10","key":"5970_CR10","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1245\/s10434-007-9403-y","volume":"14","author":"EA Newman","year":"2007","unstructured":"Newman EA, Sabel MS, Nees AV, Schott A, Diehl KM, Cimmino VM et al (2007) Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol 14(10):2946\u20132952","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"5970_CR11","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1245\/ASO.2003.05.012","volume":"10","author":"GC Balch","year":"2003","unstructured":"Balch GC, Mithani SK, Richards KR, Beauchamp RD, Kelley MC (2003) Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol 10(6):616\u2013621","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"5970_CR12","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1200\/JCO.2013.54.1177","volume":"32","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL et al (2014) Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 32(13):1365\u20131383","journal-title":"J Clin Oncol"},{"key":"5970_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jco.2014.32.18_suppl.lba1","volume":"32","author":"J-F Boileau","year":"2014","unstructured":"Boileau J-F, Poirier B, Basik M, Holloway CMB, Gaboury L, Sideris L et al (2014) Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 32:1\u20139","journal-title":"J Clin Oncol"},{"issue":"14","key":"5970_CR14","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (alliance) clinical trial. JAMA 310(14):1455\u20131461","journal-title":"JAMA"},{"issue":"2","key":"5970_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10549-018-5004-7","volume":"173","author":"J Marc","year":"2019","unstructured":"Marc J, Cecile C, Gimbergues LP, Tunon SAC, Dupre DLPF, Rouzier R (2019) Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients : the GANEA 2 study. Breast Cancer Res Treat 173(2):343\u2013352. https:\/\/doi.org\/10.1007\/s10549-018-5004-7","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"5970_CR16","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1002\/bjs.7073","volume":"97","author":"ME Straver","year":"2010","unstructured":"Straver ME, Loo CE, Alderliesten T, Rutgers EJT, Vrancken Peeters MTFD (2010) Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer. Br J Surg 97(8):1226\u20131231","journal-title":"Br J Surg"},{"issue":"10","key":"5970_CR17","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","volume":"30","author":"HJ Burstein","year":"2019","unstructured":"Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P et al (2019) Estimating the benefits of therapy for early-stage breast cancer\u202f: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 30(10):1541\u20131557. https:\/\/doi.org\/10.1093\/annonc\/mdz235","journal-title":"Ann Oncol"},{"issue":"May","key":"5970_CR18","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"533","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f9rlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 533(May):747\u2013752","journal-title":"Nature"},{"issue":"16","key":"5970_CR19","first-page":"5678","volume":"11","author":"R Rouzier","year":"2005","unstructured":"Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K et al (2005) Human cancer biology breast cancer molecular subtypes respond differently to preoperative chemotherapy. Hum Cancer Biol 11(16):5678\u20135686","journal-title":"Hum Cancer Biol"},{"issue":"9938","key":"5970_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164\u2013172. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8","journal-title":"Lancet"},{"issue":"16","key":"5970_CR21","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","volume":"23","author":"AU Buzdar","year":"2005","unstructured":"Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676\u20133685","journal-title":"J Clin Oncol"},{"issue":"9712","key":"5970_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER. Lancet 375(9712):377\u2013384. https:\/\/doi.org\/10.1016\/S0140-6736(09)61964-4","journal-title":"Lancet"},{"issue":"1","key":"5970_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(11)70336-9","journal-title":"Lancet Oncol"},{"issue":"1","key":"5970_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"WM Sikov","year":"2015","unstructured":"Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM et al (2015) Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603. J Clin Oncol 33(1):13\u201321","journal-title":"J Clin Oncol"},{"issue":"7","key":"5970_CR25","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","volume":"15","author":"G Von Minckwitz","year":"2014","unstructured":"Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M et al (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15(7):747\u2013756","journal-title":"Lancet Oncol"},{"issue":"9","key":"5970_CR26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810\u2013821","journal-title":"N Engl J Med"},{"issue":"5","key":"5970_CR27","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/tbj.13763","volume":"26","author":"S Fernandez-Gonzalez","year":"2020","unstructured":"Fernandez-Gonzalez S, Falo C, Pla MJ, Verdaguer P, Nu\u00f1ez D, Guma A et al (2020) Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapy. Breast J 26(5):888\u2013896","journal-title":"Breast J"},{"issue":"3","key":"5970_CR28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1200\/JCO.18.01624","volume":"37","author":"S Johnston","year":"2019","unstructured":"Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C et al (2019) Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor\u2013positive early breast cancer: pallet trial. J Clin Oncol 37(3):178\u2013189","journal-title":"J Clin Oncol"},{"issue":"17","key":"5970_CR29","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"MJ Ellis","year":"2011","unstructured":"Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A et al (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int. J Clin Oncol 29(17):2342\u20132349","journal-title":"J Clin Oncol"},{"issue":"5","key":"5970_CR30","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1148\/rg.335125214","volume":"33","author":"T Tirkes","year":"2013","unstructured":"Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K (2013) Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics 33(5):1323\u20131341","journal-title":"Radiographics"},{"issue":"11","key":"5970_CR31","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/jnci\/djh142","volume":"96","author":"DR McCready","year":"2004","unstructured":"McCready DR, Yong WS, Ng AKT, Miller N, Done S, Youngson B (2004) Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and false-negative rates. J Natl Cancer Inst 96(11):873\u2013875","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"5970_CR32","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2214\/AJR.07.2460","volume":"191","author":"DG Bedi","year":"2008","unstructured":"Bedi DG, Krishnamurthy R, Krishnamurthy S, Edeiken BS, Le-Petross H, Fornage BD et al (2008) Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: vitro sonographic study. Am J Roentgenol 191(3):646\u2013652. https:\/\/doi.org\/10.2214\/AJR.07.2460","journal-title":"Am J Roentgenol"},{"issue":"11","key":"5970_CR33","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","volume":"142","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, McShane LM, Hammond MEH, Allison KH, Fitzgibbons P, Press MF et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med 142(11):1364\u20131382","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"5970_CR34","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","volume":"35","author":"WF Symmans","year":"2017","unstructured":"Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M et al (2017) Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol 35(10):1049\u20131060","journal-title":"J Clin Oncol"},{"issue":"4","key":"5970_CR35","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/SLA.0000000000000924","volume":"260","author":"JC Boughey","year":"2014","unstructured":"Boughey JC, McCall LM, Ballman KV, Mittendorf EA, Ahrendt GM, Wilke LG et al (2014) Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg 260(4):608\u2013614","journal-title":"Ann Surg"},{"issue":"3","key":"5970_CR36","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA 321(3):288\u2013300","journal-title":"JAMA"},{"issue":"43","key":"5970_CR37","first-page":"1","volume":"94","author":"JY Kim","year":"2015","unstructured":"Kim JY, Park HS, Kim S, Ryu J, Park S, Kim SIL (2015) Prognostic nomogram for prediction of axillary pathologic complete response after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer. Medicine 94(43):1\u20139","journal-title":"Medicine"},{"issue":"11","key":"5970_CR38","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","volume":"23","author":"A Mamtani","year":"2016","unstructured":"Mamtani A, Barrio AV, King TA, Van Zee KJ, Plitas G, Pilewskie M et al (2016) How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol 23(11):3467\u20133474","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"5970_CR39","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1245\/s10434-015-5052-8","volume":"23","author":"EJ Diego","year":"2016","unstructured":"Diego EJ, McAuliffe PF, Soran A, McGuire KP, Johnson RR, Bonaventura M et al (2016) Axillary staging after neoadjuvant chemotherapy for breast cancer: a pilot study combining sentinel lymph node biopsy with radioactive seed localization of pre-treatment positive axillary lymph nodes. Ann Surg Oncol 23(5):1549\u20131553","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"5970_CR40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.21037\/gs.2017.11.04","volume":"7","author":"TC Gillespie","year":"2018","unstructured":"Gillespie TC, Sayegh HE, Brunelle CL, Daniell KM, Taghian AG (2018) Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surg 7(4):379\u2013403","journal-title":"Gland Surg"},{"issue":"16","key":"5970_CR41","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1158\/1078-0432.CCR-04-2421","volume":"11","author":"R Rouzier","year":"2005","unstructured":"Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678\u20135685","journal-title":"Clin Cancer Res"},{"issue":"7","key":"5970_CR42","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14(7):609\u2013618","journal-title":"Lancet Oncol"},{"issue":"4","key":"5970_CR43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.clbc.2016.02.009","volume":"16","author":"K Enokido","year":"2016","unstructured":"Enokido K, Watanabe C, Nakamura S, Ogiya A, Osako T, Akiyama F et al (2016) Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with an initial diagnosis of cytology-proven lymph node-positive breast cancer. Clin Breast Cancer 16(4):299\u2013304","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"5970_CR44","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","volume":"3","author":"M Pilewskie","year":"2017","unstructured":"Pilewskie M, Morrow M (2017) Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol 3(4):549\u2013555","journal-title":"JAMA Oncol"},{"issue":"2","key":"5970_CR45","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00404-019-05428-x","volume":"301","author":"M Banys-Paluchowski","year":"2020","unstructured":"Banys-Paluchowski M, Gruber IV, Hartkopf A, Paluchowski P, Krawczyk N, Marx M et al (2020) Axillary ultrasound for prediction of response to neoadjuvant therapy in the context of surgical strategies to axillary dissection in primary breast cancer: a systematic review of the current literature. Arch Gynecol Obstet 301(2):341\u2013353. https:\/\/doi.org\/10.1007\/s00404-019-05428-x","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"5970_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1148\/radiol.2019190014","volume":"293","author":"R Kim","year":"2019","unstructured":"Kim R, Chang JM, Lee HB, Lee SH, Kim SY, Kim ES et al (2019) Predicting axillary response to neoadjuvant chemotherapy: breast MRI and US in patients with node-positive breast cancer. Radiology 293(1):49\u201357","journal-title":"Radiology"},{"issue":"3","key":"5970_CR47","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/annonc\/mdp348","volume":"21","author":"S Rodenhuis","year":"2009","unstructured":"Rodenhuis S, Mandjes IAM, Wesseling J, van de Vijver MJ, Peeters MJTDFV, Sonke GS et al (2009) A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. Ann Oncol 21(3):481\u2013487. https:\/\/doi.org\/10.1093\/annonc\/mdp348","journal-title":"Ann Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05970-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05970-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05970-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T01:16:54Z","timestamp":1634433414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05970-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,17]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["5970"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05970-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,17]]},"assertion":[{"value":"6 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors declare that we have no conflict of interest. The authors alone are responsible for the content and writing of the paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. As a retrospective study, the patient did not receive any specific informed consent for the study. The patients signed the informed consent for the usual procedure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}